feed,title,long_url,short_url
BioRxiv,SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination,https://biorxiv.org/cgi/content/short/2021.05.04.442663v1?rss=1,https://j.mp/3b6V8EF
BioRxiv,SARS-CoV-2 B.1.1.7 and B.1.351 variants of concern induce lethal disease in K18-hACE2 transgenic mice despite convalescent plasma therapy,https://biorxiv.org/cgi/content/short/2021.05.05.442784v1?rss=1,https://j.mp/3nPqogy
BioRxiv,Single-virus fusion measurements yield an opportunistic model for SARS-CoV-2 fusion,https://biorxiv.org/cgi/content/short/2021.05.04.442634v1?rss=1,https://j.mp/3nVHEAL
BioRxiv,"Durable antibody responses in staff at two long-term care facilities, during and post SARS-CoV-2 outbreaks",https://biorxiv.org/cgi/content/short/2021.05.04.442699v1?rss=1,https://j.mp/3xKCsV7
BioRxiv,Uncovering cryptic pockets in the SARS-CoV-2 spike glycoprotein,https://biorxiv.org/cgi/content/short/2021.05.05.442536v1?rss=1,https://j.mp/3xJlyWR
